AAP
FENC icon

Arax Advisory Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Arax Advisory Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-188
Closed -$1.76K – 4233
2025
Q3 		$1.76K Buy
+188
New +$1.63K ﹤0.01% 3143

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arax Advisory Partners's FENC Position: Q4 2025 in Review

Arax Advisory Partners sold out of Fennec Pharmaceuticals (FENC) in Q4 2025, closing a stake of 188 shares — an estimated $1.76K sold.

Arax Advisory Partners first reported a position in FENC in Q3 2025 and held it in 1 quarter. The position peaked at $1.76K in Q3 2025. 96 funds tracked by Wall St. Rank hold FENC as of Q4 2025.

  • Arax Advisory Partners reported no remaining Fennec Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 188 Fennec Pharmaceuticals shares in Q4 2025, an estimated $1.76K.
  • Arax Advisory Partners first reported a position in Fennec Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Fennec Pharmaceuticals position peaked at $1.76K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.